

Biotest Group: Creating Value. Living Values.




UniCredit Group - German Investment Conference 2009

Dr. Michael Ramroth

22 September, 2009


H1 2009 - Highlights




- Biotest Group Sales up by 13.4% in H1 2009 and EBIT increased by 6.5%
- Confirmation of 2009 Guidance: Sales +10% and EBIT at € 55m
- Medical Diagnostics: Exclusive negotiations with one party to sell the business area
- Production capacity expansion
- Biotherapeutics: further data demonstrating efficacy of BT-061 and phase I of BT-062 according to schedule
- Partnering process for BT-061 on track

Sales and EBIT continue to increase

Sales (in € million)




EBIT (in € million)



Increase in profit in H1 2009

EBT and EAT (in € million)



- Rise in earnings before tax (EBT), due to more favourable financial result as a result of lower interest expenses
- Earnings after tax (EAT) at € 16 million
- Tax ratio: 31.3% (H1 2008 : 28.7%)




Biotest Group: Creating Value. Living Values.

Plasma Proteins

Plasma Proteins business at a glance


Biotest Plasma Protein products



- Global market share: 3%
- Market share in relevant markets (GER, AUT, CH, GRE, UK): 14%
- Intratect® market share in GER, AUT, CH: > 16%, in UK: > 8%
- World market leader with Cytotect® and Varitect®
- Leading position with Hepatect® in Europe and Nabi HB™ in USA
- Biotest covers full value creation chain: plasma sourcing, production, distribution
 ⇒ vertical integration leads to rationalisation and higher productivity

Plasma Proteins: further growth in sales, but at a slower rate


Plasma Proteins: sales volume (in € million)




- Sales in Plasma Proteins jumped by 37% in 2008 (incl. BPC for the first time)
- Contribution BPC: €64.1m
- In H1 2009 Plasma Protein sales increased by 14.5% to € 194.3 million

Demand for Plasma Proteins is growing, but at a slower rate

Global IVIG market (in tonnes)




- New indications and higher dosages per capita drive demand for immunoglobulins
- Decrease of prices in major European markets and US

 = Growth (over a 2-year period)

Source: Biotest research, MRB, PPTA, Review of Australia's Plasma Fractionation Arrangements (Feb 2006)

Immunoglobulins: approval of U.S.-IVIG bears significant upward potential

IVIG world market 2007: volume (in tonnes) and regional distribution (in %)



- Total volume IVIG world market as of 2008: ~ 90 tons
- USA by far the most important market for IVIG worldwide
- Registration of BPC's U.S.-IVIG (comparable to Intratect®) expected for H1 2011

Sources: MRB, APFA, UBS, Biotest Market Research

Plasma Proteins: ongoing and new product development

European approval expected in 2009 (centralised procedure):

Zutectra



Hepatitis B immunoglobulin for prophylactic treatment of reinfection following liver transplantation, administered subcutaneously – self-medication possible

Approval after 2010:

IVIG (USA):

Phase III completed by end of May 2009,
Final evaluation available: good results with respect to safety and efficacy
registration scheduled for H1 2011

IgM concentrate:

Clinical development Phase I was started in Q2 2009
First part of Phase I finalized in Q3 2009
Good tolerability observed

Cytotect®: significant large-scale trial has started

Indication: prevention of prenatal cytomegalovirus infection of the foetus in women who were infected by the virus for the first time.



- Phase III trial to confirm existing positive results from a previous study
- High ethical relevance
- Comprehensive immunoscreening required (up to 20,000 tests)
- Following initial difficulties, trial is fully underway: more than 2,500 pregnant women have been screened
- Accelerated recruitment, new centers included in the study (e.g. England, Poland, Hungary, Austria)

Intratect® – upside potential from additional indication

Human immunoglobulin for intravenous use (IVIg)



- Chronic idiopathic pain syndrome (CIPS) (fibromyalgia) - Phase III trial completed
- Excellent clinical response in 30% of patients
- 1 - 2 % of the population in Europe and US are suffering from CIPS.
 - 5 % of them do not respond to conventional therapy (about 400,000 people)

Outlook for Plasma Proteins: steady growth

- Internationalisation of business through new developments and the expansion of existing approvals
- Continued growth at a slower rate is expected
- Decrease of prices continues, but no price erosion





Biotest: Creating Value. Living Values.

Biotherapeutics

Biotherapeutics: investment in projects with potential


Common features of Biotest's monoclonal antibodies

- High medical need
- Rapidly growing markets
- Blockbuster potential

Lead indications


BT-061	Rheumatoid Arthritis, Psoriasis
BT-062	Multiple Myeloma
BT-063	Systemic Lupus Erythematosus and other autoimmune diseases

R&D expense – Biotherapeutics (in € million)



Rheumatoid Arthritis and Psoriasis – a huge and growing market

Market volume (in US\$ million)



- Strong growth in both lead indications
- After approval: significant market share is realistic
- Blockbuster potential

(Source: Datamonitor, Commercial Insight Autoimmune Overview 2007; L.E.K, annual reports, Biotest studies)

BT-061 – overview of clinical trials

Trial 961: (Phase I)

Single dose, intravenously and subcutaneously,
healthy subjects (tolerability), (57).

Study completed

Rheumatoid arthritis

Trial 962 (Phase IIa):

Multi-dose, intravenously and
subcutaneously, placebo-
controlled, (96).

Study ongoing

Trial 971 (Phase II):

BT-061 with MTX*, multi-dose,
intravenously, placebo-
controlled (110).

**Treatment of patients of first
study group completed (N=70)**

Psoriasis

Trial 967 (Phase I/IIa):

Single dose, intravenously and
subcutaneously, placebo-
controlled, (56).

Study ongoing

Trial 973 (Phase II):

Multi-dose, intravenously and
subcutaneously, placebo-
controlled** (48).

CTA submission Sept. 2009

Very encouraging interim results from clinical trials with BT-061

Rheumatoid arthritis – Phase IIa* (No. 962 + No. 971)

- **Marked clinical improvement** with the dosage groups used to date (s.c., i.v.) in up to **62.5% of patients. (Monotherapy)**
- **Combination** BT-061 with MTX (i.v.)
- **Clinical improvement** even higher compared to monotherapy (**up to 70%** of patients)

Psoriasis – Phase I/IIa* (No. 967)

- In therapeutically relevant dosages (intravenous) **marked clinical improvement in 75% of patients.**
- PASI improved by up to 88%
- Long-lasting effect even with low dosages

More than 240 subjects involved in all trials as of July '09, efficacy in both indications, general tolerability of BT-061 is good

* Dose escalation trials: 75% of patients receive BT-061, 25% receive the placebo drug
Interim results, blinded data

Partnering for BT-061: process started successfully, positive response





Biotest strategy:

Co-development and
co-marketing with “big
pharma” from clinical
Phase III onwards

- Start of partnering process successful
- Global pharmaceutical groups approached (“big pharma”)
- Predominantly positive response
- Negotiations started with selected companies
- Agreement expected by the end of 2009 / start of 2010


BT-062 – good tolerability, first indications of efficacy



- BT-062: specific and highly effective immunotoxin: toxin part mediates high efficacy – antibody part mediates high specificity
- Phase I Study: Dose escalation study in patients with relapsed or relapsed/refractory Multiple Myeloma
- Clinical trials in 4 cancer centres in the US, open label, repeated single dose
- The agent is generally well tolerated
- Indications of efficacy already with low dosages:
 - **Aggressive progress of the disease halted in some patients for several months**
 - **Seventh dose level reached in current study**


Multiple Myeloma – unmet need and high market potential

Survival rates for MM patients in the USA




(Source: SEER Cancer Statistics Review, 1975 - 2004)

Sales of novel targeted MM therapies (in US\$ million)



(Source: Company data and Biotest analysis 2009)

BT-063 – Competitive advantages due to unique mode-of-action






BT-063 lead indication

- Systemic Lupus Erythematosus (SLE)
- High medical need: SLE incurable today, no new approval since ~ 40 years
- 2.5 million patients are suffering from SLE worldwide today

Mode-of-action

- BT-063 positively modulates the immune system in this indication
- Few other biologics in development: mostly anti B cell antibodies
- Clinical data from pilot study with six patients very promising
- **CTA approval of clinical phase I trial expected in Sept. 2009**

Outlook Biotherapeutics: reach new development stage



- Significant progress with all projects
- BT-061: partnering process ongoing
- BT-063: CTA approval expected in Sept. 2009
- Set-up of own production of monoclonal antibodies progressing well at BPC

Projects require considerable effort and are associated with risks up to the final stage.

However, they offer major opportunities for steady revenue in the long term.

2009 outlook – Strong first half year, further growth expected



- **Solid growth in H1 2009:**
 - Sales +13.4% vs. H1 /2008, growth in all segments
 - EBIT +6.5%
- Economic crisis has had no significant impact to date – however, increased vigilance is necessary
- **Reconfirmed Targets for 2009:**
 - Sales +10%
 - EBIT at previous year's level (€55 million)

Disclaimer

This document contains forward-looking statements on overall economic developments as well as on the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and thus are subject to risks and elements of uncertainty that could result in deviation of actual developments from expected developments.

The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

All comparative figures relate to the corresponding last year's period, unless stated otherwise.

Contact and Financial Calendar 2009/ 2010

Biotest AG

Landsteinerstraße 3-5

D-63303 Dreieich

Phone: +49 (0) 6103 - 801 -0

Fax: +49 (0) 6103 - 801 -150

E-Mail: mail@biotest.de

Web: www.biotest.de

Investor Relations:

Dr. Monika Buttkereit

Head of Investor Relations

Phone: +49 (0) 6103 - 801 -4406

Fax: +49 (0) 6103 - 801 -347

E-Mail: investor_relations@biotest.de

Financial Calendar 2009/ 2010

05 November 2009 Quarterly Report for
Q3 2009

05 November 2009 Analysts Conference